Multi-omics Analysis of TMED3 as a Potential Prognostic Biomarker Across Six Cancer Types
Oncology Advances · 30.06.2026 · 4 (2) · e00003
DOI: 10.14218/ona.2026.00003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Advances, online erschienen am 28.06.2026. Verfasst von Zhui Ke und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The clinical and genetic characteristics of TMED3, a p24-family protein, across different cancer types remain incompletely understood. This study aimed to evaluate its expression patterns, prognostic relevance, epigenetic regulation, immune associations, genetic alterations, functional networks, and chemical-gene interactions across six cancer types.
Zitieren
APA
Ke, Z., Ji, P., Lu, J., Yang, Y., Guo, X., Li, Y., & Chen, L. (2026). Multi-omics Analysis of TMED3 as a Potential Prognostic Biomarker Across Six Cancer Types. Oncology Advances, 4(2), e00003. https://doi.org/10.14218/ona.2026.00003
Vancouver
Ke Z, Ji P, Lu J, Yang Y, Guo X, Li Y, et al. Multi-omics Analysis of TMED3 as a Potential Prognostic Biomarker Across Six Cancer Types. Oncology Advances. 2026;4(2):e00003. doi:10.14218/ona.2026.00003
BibTeX
@article{Ke2026,
author = {Ke, Zhui and Ji, Peng and Lu, Jingyi and Yang, Yongqing and Guo, Xianling and Li, Yue and Chen, Lan},
title = {Multi-omics Analysis of TMED3 as a Potential Prognostic Biomarker Across Six Cancer Types},
journal = {Oncology Advances},
year = {2026},
volume = {4},
number = {2},
pages = {e00003},
doi = {10.14218/ona.2026.00003}
}
EUVIMED